Insider Transaction Report for Adaptive Biotechnologies Corp

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reported a series of transactions on April 27, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Rubinstein acquired 14,707 shares of Common Stock at $8.46 per share and disposed of 19,037 shares of Common Stock at a weighted average price of $14.23 per share, with individual sales prices ranging from $14.08 to $14.34. Additionally, Rubinstein exercised a stock option to buy 14,707 shares of Common Stock, with an exercise price of $8.46 per share, and disposed of these shares. Following these transactions, Rubinstein holds 396,839 shares directly. The stock options exercised were part of a grant that vests over time, with 1/4 vesting initially and the remainder vesting monthly.